Development of specific immunomodulatory agents for Multiple Sclerosis affecting the brainstem and cerebellum (2009–2011)
The aim of this project is to develop immune-modulating peptides that will specificallt inhibit immune responses against the most abundant myelin protein in the central nervous system which is caled PLP. PLP comes under immune attack in poeple whose Multiple Sclerosis affects the parts of the brain that control functions such as balance. The aim is to prove that the immune-modulating peptides will be able to specifically prevent damage to these areas of the brain, without causing unwanted side-effects. The work will be done using peripheral blood leukocytes from patients with MS.